Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
60
UPC Quote, Financials, Valuation and Earnings
Last price:
$4.20
Seasonality move
:
-34.25%
Day range:
$3.78 - $4.50
52-week range:
$2.51 - $28.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.04x
P/B ratio:
0.04x
Volume:
110.3K
Avg. volume:
47.9K
1-year change:
-83.1%
Market cap:
$2.4M
Revenue:
$23M
EPS (TTM):
-$76.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UPC
Universe Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UPC
Universe Pharmaceuticals, Inc.
|
$4.29 | -- | $2.4M | -- | $0.00 | 0% | 0.04x |
|
ADAG
Adagene, Inc.
|
$1.85 | $9.22 | $87.2M | -- | $0.00 | 0% | 832.60x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.78 | $4.00 | $16.1M | -- | $0.00 | 0% | 0.46x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.31 | -- | $4.3M | -- | $0.00 | 0% | 1.06x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.58 | $49.17 | $2.1B | -- | $0.00 | 0% | 4.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UPC
Universe Pharmaceuticals, Inc.
|
19.58% | 3.613 | 81.51% | 1.25x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UPC
Universe Pharmaceuticals, Inc.
|
-- | -- | -42.98% | -49.07% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Universe Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns UPC or ADAG?
Adagene, Inc. has a net margin of -- compared to Universe Pharmaceuticals, Inc.'s net margin of --. Universe Pharmaceuticals, Inc.'s return on equity of -49.07% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital UPCUniverse Pharmaceuticals, Inc.-- -- $33.3M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About UPC or ADAG?
Universe Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 398.61%. Given that Adagene, Inc. has higher upside potential than Universe Pharmaceuticals, Inc., analysts believe Adagene, Inc. is more attractive than Universe Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UPCUniverse Pharmaceuticals, Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is UPC or ADAG More Risky?
Universe Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock UPC or ADAG?
Universe Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Universe Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UPC or ADAG?
Universe Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. Universe Pharmaceuticals, Inc.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, Universe Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Universe Pharmaceuticals, Inc. is 0.04x versus 832.60x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UPCUniverse Pharmaceuticals, Inc.0.04x -- -- -- ADAGAdagene, Inc.832.60x -- -- --
-
Which has Higher Returns UPC or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Universe Pharmaceuticals, Inc.'s net margin of -353.92%. Universe Pharmaceuticals, Inc.'s return on equity of -49.07% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital UPCUniverse Pharmaceuticals, Inc.-- -- $33.3M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About UPC or CASI?
Universe Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 431.07%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Universe Pharmaceuticals, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Universe Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UPCUniverse Pharmaceuticals, Inc.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is UPC or CASI More Risky?
Universe Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock UPC or CASI?
Universe Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Universe Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UPC or CASI?
Universe Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Universe Pharmaceuticals, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Universe Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Universe Pharmaceuticals, Inc. is 0.04x versus 0.46x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UPCUniverse Pharmaceuticals, Inc.0.04x -- -- -- CASICASI Pharmaceuticals, Inc.0.46x -- $3.1M -$10.9M
-
Which has Higher Returns UPC or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to Universe Pharmaceuticals, Inc.'s net margin of -86.16%. Universe Pharmaceuticals, Inc.'s return on equity of -49.07% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital UPCUniverse Pharmaceuticals, Inc.-- -- $33.3M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About UPC or CPHI?
Universe Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Universe Pharmaceuticals, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Universe Pharmaceuticals, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UPCUniverse Pharmaceuticals, Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is UPC or CPHI More Risky?
Universe Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock UPC or CPHI?
Universe Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Universe Pharmaceuticals, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UPC or CPHI?
Universe Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Universe Pharmaceuticals, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Universe Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Universe Pharmaceuticals, Inc. is 0.04x versus 1.06x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UPCUniverse Pharmaceuticals, Inc.0.04x -- -- -- CPHIChina Pharma Holdings, Inc.1.06x -- $756.2K -$651.5K
-
Which has Higher Returns UPC or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Universe Pharmaceuticals, Inc.'s net margin of --. Universe Pharmaceuticals, Inc.'s return on equity of -49.07% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital UPCUniverse Pharmaceuticals, Inc.-- -- $33.3M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About UPC or SVA?
Universe Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Universe Pharmaceuticals, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Universe Pharmaceuticals, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings UPCUniverse Pharmaceuticals, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is UPC or SVA More Risky?
Universe Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock UPC or SVA?
Universe Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Universe Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios UPC or SVA?
Universe Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Universe Pharmaceuticals, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Universe Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Universe Pharmaceuticals, Inc. is 0.04x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UPCUniverse Pharmaceuticals, Inc.0.04x -- -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns UPC or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Universe Pharmaceuticals, Inc.'s net margin of -30.98%. Universe Pharmaceuticals, Inc.'s return on equity of -49.07% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital UPCUniverse Pharmaceuticals, Inc.-- -- $33.3M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About UPC or ZLAB?
Universe Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 164.64%. Given that Zai Lab Ltd. has higher upside potential than Universe Pharmaceuticals, Inc., analysts believe Zai Lab Ltd. is more attractive than Universe Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UPCUniverse Pharmaceuticals, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is UPC or ZLAB More Risky?
Universe Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock UPC or ZLAB?
Universe Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Universe Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UPC or ZLAB?
Universe Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Universe Pharmaceuticals, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Universe Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Universe Pharmaceuticals, Inc. is 0.04x versus 4.51x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UPCUniverse Pharmaceuticals, Inc.0.04x -- -- -- ZLABZai Lab Ltd.4.51x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
